{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T16:22:06Z","timestamp":1770222126762,"version":"3.49.0"},"reference-count":139,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T00:00:00Z","timestamp":1769299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) coexist in 40\u201360% of cases and mutually reinforce each other through adverse electrical, cellular, and functional remodelling. There is considerable overlap in signs and symptoms, and diagnosis may be challenging due to nonspecific clinical presentations and chronic course. AF is clearly linked with worsening morbidity and mortality in HFpEF with higher rates of HF hospitalizations, HF progression, stroke, systemic embolism, and all-cause death. Optimal management of HFpEF-AF patients requires aggressive treatment of comorbidities and risk factor modification. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have demonstrated consistent benefit with respect to HF hospitalizations, symptoms and exercise haemodynamics, and potential to reduce AF burden. Gastric inhibitory polypeptide (GIP)\/glucagon-like peptide-1 (GLP-1) agonists, mineralocorticoid receptor antagonists (MRAs), angiotensin receptor-neprilysin inhibitors (ARNIs), and statins may provide benefit in selected phenotypes, though evidence remains heterogeneous. A rhythm control strategy in the early clinical course of HFpEF might be a reasonable strategy to improve symptoms and delay both AF and HFpEF disease progression. Catheter ablation appears to improve exercise haemodynamics and quality of life, and observational data suggest it may reduce mortality and HF hospitalization, though current evidence is inconsistent and not yet definitive. Emerging device-based and molecular therapies could represent promising avenues for future research. Overall, early detection of AF, comprehensive risk-factor modification, and tailored rhythm-control strategies are central to improving outcomes in the HFpEF-AF overlap syndrome.<\/jats:p>","DOI":"10.3390\/jcm15030969","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T09:21:40Z","timestamp":1769505700000},"page":"969","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Preserved Ejection, Lost Rhythm: A Narrative Review of the Pathophysiology and Management of Heart Failure with Preserved Ejection Fraction and Concomitant Atrial Fibrillation"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7520-3166","authenticated-orcid":false,"given":"Andrea","family":"Ballatore","sequence":"first","affiliation":[{"name":"Division of Cardiology, Cardiovascular and Thoracic Department, \u201cCitt\u00e0 della Salute e della Scienza\u201d Hospital, 10126 Turin, Italy"},{"name":"Department of Medical Sciences, University of Turin, 10124 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3191-4875","authenticated-orcid":false,"given":"Alan","family":"Poggio","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Cardiovascular and Thoracic Department, \u201cCitt\u00e0 della Salute e della Scienza\u201d Hospital, 10126 Turin, Italy"},{"name":"Department of Medical Sciences, University of Turin, 10124 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5011-2575","authenticated-orcid":false,"given":"Andrew P.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"UBC Division of Cardiology, Gordon & and Leslie Diamond Health Care Centre, 2775 Laurel St., 9th Floor, Vancouver, BC V5Z 1M9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9475-1507","authenticated-orcid":false,"given":"Andrea","family":"Saglietto","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Cardiovascular and Thoracic Department, \u201cCitt\u00e0 della Salute e della Scienza\u201d Hospital, 10126 Turin, Italy"},{"name":"Department of Medical Sciences, University of Turin, 10124 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4940-0876","authenticated-orcid":false,"given":"Gaetano Maria","family":"De Ferrari","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Cardiovascular and Thoracic Department, \u201cCitt\u00e0 della Salute e della Scienza\u201d Hospital, 10126 Turin, Italy"},{"name":"Department of Medical Sciences, University of Turin, 10124 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6311-4270","authenticated-orcid":false,"given":"Matteo","family":"Anselmino","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Cardiovascular and Thoracic Department, \u201cCitt\u00e0 della Salute e della Scienza\u201d Hospital, 10126 Turin, Italy"},{"name":"Department of Medical Sciences, University of Turin, 10124 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/eurheartj\/ehi825","article-title":"Prevalence, Incidence and Lifetime Risk of Atrial Fibrillation: The Rotterdam Study","volume":"27","author":"Heeringa","year":"2006","journal-title":"Eur. Heart J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.15420\/cfr.2022.06","article-title":"Epidemiology and Clinical Features of Heart Failure with Preserved Ejection Fraction","volume":"8","author":"Teramoto","year":"2022","journal-title":"Card. Fail. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1161\/CIRCULATIONAHA.115.018614","article-title":"Atrial Fibrillation Begets Heart Failure and Vice Versa","volume":"133","author":"Santhanakrishnan","year":"2016","journal-title":"Circulation"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1093\/eurheartj\/ehy268","article-title":"Haemodynamics, Dyspnoea, and Pulmonary Reserve in Heart Failure with Preserved Ejection Fraction","volume":"39","author":"Obokata","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.jacc.2023.01.049","article-title":"Heart Failure with Preserved Ejection Fraction","volume":"81","author":"Borlaug","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.cjco.2024.11.017","article-title":"Trends in Global Burden and Socioeconomic Profiles of Atrial Fibrillation and Atrial Flutter: Insights from the Global Burden of Disease Study 2021","volume":"7","author":"Tan","year":"2024","journal-title":"CJC Open"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1161\/CIRCULATIONAHA.117.031622","article-title":"Sex and Race Differences in Lifetime Risk of Heart Failure with Preserved Ejection Fraction and Heart Failure with Reduced Ejection Fraction","volume":"137","author":"Pandey","year":"2018","journal-title":"Circulation"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/ejhf.483","article-title":"Epidemiology of Heart Failure: The Prevalence of Heart Failure and Ventricular Dysfunction in Older Adults over Time. A Systematic Review","volume":"18","author":"Hoes","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.jacc.2017.08.074","article-title":"Heart Failure with Preserved, Borderline, and Reduced Ejection Fraction","volume":"70","author":"Shah","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.amjcard.2013.05.063","article-title":"Estimates of Current and Future Incidence and Prevalence of Atrial Fibrillation in the U.S. Adult Population","volume":"112","author":"Colilla","year":"2013","journal-title":"Am. J. Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cardfail.2021.08.020","article-title":"Trends in Heart Failure Hospitalizations in the US from 2008 to 2018","volume":"28","author":"Clark","year":"2022","journal-title":"J. Card. Fail."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ejhf.2115","article-title":"Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association","volume":"23","author":"Bozkurt","year":"2021","journal-title":"Eur. J. Heart Fail."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/ejhf.2377","article-title":"Uncoupling between Intravascular and Distending Pressures Leads to Underestimation of Circulatory Congestion in Obesity","volume":"24","author":"Obokata","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/ejhf.3105","article-title":"Clinical Phenogroup Diversity and Multiplicity: Impact on Mechanisms of Exercise Intolerance in Heart Failure with Preserved Ejection Fraction","volume":"26","author":"Larson","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"132385","DOI":"10.1016\/j.ijcard.2024.132385","article-title":"H2FPEF and HFA-PEFF Scores Performance and the Additional Value of Cardiac Structure and Function in Patients with Atrial Fibrillation","volume":"413","author":"Bonelli","year":"2024","journal-title":"Int. J. Cardiol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Baba, M., Yoshida, K., and Ieda, M. (2019). Clinical Applications of Natriuretic Peptides in Heart Failure and Atrial Fibrillation. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20112824"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.jchf.2024.01.015","article-title":"Utility and Validity of the HFA-PEFF and H2FPEF Scores in Patients with Symptomatic Atrial Fibrillation","volume":"12","author":"Ariyaratnam","year":"2024","journal-title":"JACC Heart Fail."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.echo.2025.03.011","article-title":"Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography and for Heart Failure with Preserved Ejection Fraction Diagnosis: An Update from the American Society of Echocardiography","volume":"38","author":"Nagueh","year":"2025","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1038\/s41591-024-03140-1","article-title":"An Evidence-Based Screening Tool for Heart Failure with Preserved Ejection Fraction: The HFpEF-ABA Score","volume":"30","author":"Reddy","year":"2024","journal-title":"Nat. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1161\/CIRCULATIONAHA.118.034646","article-title":"A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure with Preserved Ejection Fraction","volume":"138","author":"Reddy","year":"2018","journal-title":"Circulation"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/ejhf.1741","article-title":"How to Diagnose Heart Failure with Preserved Ejection Fraction: The HFA\u2013PEFF Diagnostic Algorithm: A Consensus Recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"22","author":"Pieske","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ccep.2020.11.004","article-title":"Atrial Fibrillation and Heart Failure: Epidemiology, Pathophysiology, Prognosis, and Management","volume":"13","author":"Ariyaratnam","year":"2021","journal-title":"Card. Electrophysiol. Clin."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrcardio.2015.191","article-title":"Comorbidity of Atrial Fibrillation and Heart Failure","volume":"13","author":"Ling","year":"2016","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A Novel Paradigm for Heart Failure with Preserved Ejection Fraction","volume":"62","author":"Paulus","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","article-title":"Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure with Preserved Ejection Fraction","volume":"136","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jchf.2019.03.021","article-title":"The Role of the Pericardium in Heart Failure: Implications for Pathophysiology and Treatment","volume":"7","author":"Borlaug","year":"2019","journal-title":"JACC Heart Fail."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1161\/CIRCULATIONAHA.119.042996","article-title":"Interdependence of Atrial Fibrillation and Heart Failure with a Preserved Ejection Fraction Reflects a Common Underlying Atrial and Ventricular Myopathy","volume":"141","author":"Packer","year":"2020","journal-title":"Circulation"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1161\/CIRCULATIONAHA.121.058592","article-title":"Longitudinal Evolution of Cardiac Dysfunction in Heart Failure and Preserved Ejection Fraction with Normal Natriuretic Peptide Levels","volume":"146","author":"Sorimachi","year":"2022","journal-title":"Circulation"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/eurheartj\/ehy809","article-title":"Deterioration in Right Ventricular Structure and Function over Time in Patients with Heart Failure and Preserved Ejection Fraction","volume":"40","author":"Obokata","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1161\/01.CIR.92.7.1954","article-title":"Atrial Fibrillation Begets Atrial Fibrillation. A Study in Awake Chronically Instrumented Goats","volume":"92","author":"Wijffels","year":"1995","journal-title":"Circulation"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0008-6363(02)00258-4","article-title":"Electrical, Contractile and Structural Remodeling during Atrial Fibrillation","volume":"54","author":"Allessie","year":"2002","journal-title":"Cardiovasc. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1161\/01.CIR.0000055314.10801.4F","article-title":"Electrical and Contractile Remodeling during the First Days of Atrial Fibrillation Go Hand in Hand","volume":"107","author":"Schotten","year":"2003","journal-title":"Circulation"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.pcad.2005.06.014","article-title":"Electrical and Structural Remodeling: Role in the Genesis and Maintenance of Atrial Fibrillation","volume":"48","author":"Schoonderwoerd","year":"2005","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1161\/01.CIR.0000062689.04037.3F","article-title":"Reverse Structural and Gap-Junctional Remodeling after Prolonged Atrial Fibrillation in the Goat","volume":"107","author":"Ausma","year":"2003","journal-title":"Circulation"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1159\/000347126","article-title":"Increased Expression of Connective Tissue Growth Factor and Transforming Growth Factor-Beta-1 in Atrial Myocardium of Patients with Chronic Atrial Fibrillation","volume":"124","author":"Li","year":"2013","journal-title":"Cardiology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jelectrocard.2005.06.096","article-title":"Electrical Coupling of Fibroblasts and Myocytes: Relevance for Cardiac Propagation","volume":"38","author":"Kohl","year":"2005","journal-title":"J. Electrocardiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.15420\/aer.2022.10","article-title":"Safety, Efficacy and Prognostic Benefit of Atrial Fibrillation Ablation in Heart Failure with Preserved Ejection Fraction","volume":"11","author":"Johner","year":"2022","journal-title":"Arrhythm. Electrophysiol. Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e003238","DOI":"10.1161\/CIRCHEARTFAILURE.115.003238","article-title":"Left Atrial Remodeling and Atrioventricular Coupling in a Canine Model of Early Heart Failure with Preserved Ejection Fraction","volume":"9","author":"Zakeri","year":"2016","journal-title":"Circ. Heart Fail."},{"key":"ref_39","first-page":"495","article-title":"The Pig as a Model of Tachycardia and Dilated Cardiomyopathy","volume":"40","author":"Hendrick","year":"1990","journal-title":"Lab. Anim. Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrcardio.2016.163","article-title":"Neurohormonal Activation in Heart Failure with Reduced Ejection Fraction","volume":"14","author":"Hartupee","year":"2017","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.jacc.2008.11.054","article-title":"Paroxysmal Lone Atrial Fibrillation Is Associated with an Abnormal Atrial Substrate: Characterizing the \u201cSecond Factor\u201d","volume":"53","author":"Stiles","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1016\/j.jacc.2019.02.061","article-title":"Atrial Functional Mitral Regurgitation: JACC Review Topic of the Week","volume":"73","author":"Deferm","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1161\/CIRCRESAHA.114.303772","article-title":"Role of the Autonomic Nervous System in Atrial Fibrillation: Pathophysiology and Therapy","volume":"114","author":"Chen","year":"2014","journal-title":"Circ. Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1038\/s41598-021-84133-9","article-title":"Disproportionate Left Atrial Myopathy in Heart Failure with Preserved Ejection Fraction among Participants of the PROMIS-HFpEF Study","volume":"11","author":"Patel","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.jchf.2023.01.030","article-title":"Exercise-Induced Left Atrial Hypertension in Heart Failure with Preserved Ejection Fraction","volume":"11","author":"Litwin","year":"2023","journal-title":"JACC Heart Fail."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e016424","DOI":"10.1161\/CIRCIMAGING.123.016424","article-title":"Left Atrial Roof Enlargement Is a Distinct Feature of Heart Failure with Preserved Ejection Fraction","volume":"17","author":"Backhaus","year":"2024","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jchf.2019.03.005","article-title":"Heart Failure and Atrial Fibrillation, Like Fire and Fury","volume":"7","author":"Carlisle","year":"2019","journal-title":"JACC Heart Fail."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.jacc.2023.03.393","article-title":"2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure with Preserved Ejection Fraction","volume":"81","author":"Kittleson","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/ejhf.2122","article-title":"A Prospective STudy Using invAsive Haemodynamic Measurements foLLowing Catheter Ablation for AF and Early HFpEF: STALL AF-HFpEF","volume":"23","author":"Sugumar","year":"2021","journal-title":"Eur. J. Heart Fail."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1161\/CIRCULATIONAHA.113.001475","article-title":"Temporal Relationship and Prognostic Significance of Atrial Fibrillation in Heart Failure Patients with Preserved Ejection Fraction: A Community-Based Study","volume":"128","author":"Zakeri","year":"2013","journal-title":"Circulation"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1093\/eurheartj\/eht066","article-title":"Incidence and Epidemiology of New Onset Heart Failure with Preserved vs. Reduced Ejection Fraction in a Community-Based Cohort: 11-Year Follow-up of PREVEND","volume":"34","author":"Brouwers","year":"2013","journal-title":"Eur. Heart J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e009835","DOI":"10.1161\/CIRCHEARTFAILURE.122.009835","article-title":"Is There a Role for Catheter Ablation of Atrial Fibrillation in the Treatment of Patients with Heart Failure and Preserved Ejection Fraction?","volume":"15","author":"Zakeri","year":"2022","journal-title":"Circ. Heart Fail."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1161\/CIRCHEARTFAILURE.113.000568","article-title":"Impact of Atrial Fibrillation on Exercise Capacity in Heart Failure with Preserved Ejection Fraction: A RELAX Trial Ancillary Study","volume":"7","author":"Zakeri","year":"2014","journal-title":"Circ. Heart Fail."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1161\/CIRCHEARTFAILURE.114.001667","article-title":"Left Atrial Remodeling and Function in Advanced Heart Failure with Preserved or Reduced Ejection Fraction","volume":"8","author":"Melenovsky","year":"2015","journal-title":"Circ. Heart Fail."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Fauchier, L., Bisson, A., and Bodin, A. (2023). Heart Failure with Preserved Ejection Fraction and Atrial Fibrillation: Recent Advances and Open Questions. BMC Med., 21.","DOI":"10.1186\/s12916-023-02764-3"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jacc.2020.07.009","article-title":"Atrial Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction and Atrial Fibrillation","volume":"76","author":"Reddy","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.hlc.2020.10.010","article-title":"Meta-Analysis of Atrial Fibrillation and Outcomes in Patients with Heart Failure and Preserved Ejection Fraction","volume":"30","author":"Liu","year":"2021","journal-title":"Heart Lung Circ."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jchf.2022.01.018","article-title":"Atrial Fibrillation in Heart Failure with Preserved Ejection Fraction","volume":"10","author":"Cikes","year":"2022","journal-title":"JACC Heart Fail."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"euad095","DOI":"10.1093\/europace\/euad095","article-title":"Atrial Fibrillation Can Adversely Impact Heart Failure with Preserved Ejection Fraction by Its Association with Heart Failure Progression and Mortality: A Post-Hoc Propensity Score-Matched Analysis of the TOPCAT Americas Trial","volume":"25","author":"Saksena","year":"2023","journal-title":"Europace"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1111\/jce.16625","article-title":"Atrial Fibrillation (AF) and Heart Failure with Preserved Ejection Fraction (HFpEF): Advances and Challenges","volume":"36","author":"Saksena","year":"2025","journal-title":"Cardiovasc. Electrophysiol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1002\/ehf2.13264","article-title":"Stroke and Systemic Embolism in Patients with Atrial Fibrillation and Heart Failure According to Heart Failure Type","volume":"8","author":"Uhm","year":"2021","journal-title":"ESC Heart Fail."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.jacc.2011.11.040","article-title":"Impact of Non-Cardiac Comorbidities on Morbidity and Mortality in a Predominantly Male Population with Heart Failure and Preserved versus Reduced Ejection Fraction","volume":"59","author":"Ather","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1093\/eurheartj\/ehx739","article-title":"Targeted Therapy of Underlying Conditions Improves Sinus Rhythm Maintenance in Patients with Persistent Atrial Fibrillation: Results of the RACE 3 Trial","volume":"39","author":"Rienstra","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/ejhf.1060","article-title":"Systolic Blood Pressure and Cardiovascular Outcomes in Heart Failure with Preserved Ejection Fraction: An Analysis of the TOPCAT Trial","volume":"20","author":"Selvaraj","year":"2018","journal-title":"Eur. J. Heart Fail."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.jacc.2015.03.002","article-title":"Long-Term Effect of Goal-Directed Weight Management in an Atrial Fibrillation Cohort: A Long-Term Follow-Up Study (LEGACY)","volume":"65","author":"Pathak","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1001\/jama.2013.280521","article-title":"Effect of Weight Reduction and Cardiometabolic Risk Factor Management on Symptom Burden and Severity in Patients with Atrial Fibrillation: A Randomized Clinical Trial","volume":"310","author":"Abed","year":"2013","journal-title":"JAMA"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.numecd.2020.08.022","article-title":"Association of Physical Activity and Risk of Atrial Fibrillation in Heart Failure with Preserved Ejection Fraction","volume":"31","author":"Zhu","year":"2021","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1001\/jamacardio.2018.0095","article-title":"Associations of Obstructive Sleep Apnea with Atrial Fibrillation and Continuous Positive Airway Pressure Treatment: A Review","volume":"3","author":"Linz","year":"2018","journal-title":"JAMA Cardiol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1093\/eurjhf\/hfp057","article-title":"Sleep-Disordered Breathing in Heart Failure with Normal Left Ventricular Ejection Fraction","volume":"11","author":"Bitter","year":"2009","journal-title":"Eur. J. Heart Fail."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ahj.2014.12.024","article-title":"Impact of Obstructive Sleep Apnea and Continuous Positive Airway Pressure Therapy on Outcomes in Patients with Atrial Fibrillation-Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)","volume":"169","author":"Holmqvist","year":"2015","journal-title":"Am. Heart J."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/jce.14898","article-title":"Associations of Anemia with Stroke, Bleeding, and Mortality in Atrial Fibrillation: A Systematic Review and Meta-Analysis","volume":"32","author":"Tu","year":"2021","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"100507","DOI":"10.1016\/j.ijcha.2020.100507","article-title":"Clinical Relationship between Anemia and Atrial Fibrillation Recurrence after Catheter Ablation without Genetic Background","volume":"27","author":"Kim","year":"2020","journal-title":"IJC Heart Vasc."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"100739","DOI":"10.1016\/j.eclinm.2021.100739","article-title":"Outcome Trends in People with Heart Failure, Type 2 Diabetes Mellitus and Chronic Kidney Disease in the UK over Twenty Years","volume":"32","author":"Lawson","year":"2021","journal-title":"EClinicalMedicine"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Khan, Y.H., Sarriff, A., Adnan, A.S., Khan, A.H., and Mallhi, T.H. (2016). Chronic Kidney Disease, Fluid Overload and Diuretics: A Complicated Triangle. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0159335"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.ahj.2011.07.030","article-title":"Intensive Glycemic Control Has No Impact on the Risk of Heart Failure in Type 2 Diabetic Patients: Evidence from a 37,229 Patient Meta-Analysis","volume":"162","author":"Castagno","year":"2011","journal-title":"Am. Heart J."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.114.010389","article-title":"Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial","volume":"130","author":"Scirica","year":"2014","journal-title":"Circulation"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1001\/jama.298.22.2634","article-title":"Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes","volume":"298","author":"Lipscombe","year":"2007","journal-title":"JAMA"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e009770","DOI":"10.1161\/CIRCEP.121.009770","article-title":"Alcohol Consumption Reduction and Clinical Outcomes of Catheter Ablation for Atrial Fibrillation","volume":"14","author":"Takahashi","year":"2021","journal-title":"Circ. Arrhythmia Electrophysiol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"ehad655.950","DOI":"10.1093\/eurheartj\/ehad655.950","article-title":"The Association between Alcohol Consumption and Heart Failure with Reduced and Preserved Ejection Fraction: The Cardiovascular Health Study","volume":"44","author":"Hoek","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","article-title":"The SGLT2 Inhibitor Dapagliflozin in Heart Failure with Preserved Ejection Fraction: A Multicenter Randomized Trial","volume":"27","author":"Nassif","year":"2021","journal-title":"Nat. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/ejhf.2381","article-title":"Dapagliflozin and Atrial Fibrillation in Heart Failure with Reduced Ejection Fraction: Insights from DAPA-HF","volume":"24","author":"Butt","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12933-017-0658-8","article-title":"The Effect of Dapagliflozin Treatment on Epicardial Adipose Tissue Volume","volume":"17","author":"Sato","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1161\/CIRCULATIONAHA.123.065134","article-title":"Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure with Preserved Ejection Fraction: The CAMEO-DAPA Trial","volume":"148","author":"Borlaug","year":"2023","journal-title":"Circulation"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1161\/CIRCULATIONAHA.124.068788","article-title":"Dapagliflozin Enhances Arterial and Venous Compliance During Exercise in Heart Failure with Preserved Ejection Fraction: Insights from the CAMEO-DAPA Trial","volume":"150","author":"Tada","year":"2024","journal-title":"Circulation"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00395-023-01022-0","article-title":"Acute Antiarrhythmic Effects of SGLT2 Inhibitors\u2013Dapagliflozin Lowers the Excitability of Atrial Cardiomyocytes","volume":"119","author":"Paasche","year":"2024","journal-title":"Basic. Res. Cardiol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/CIRCULATIONAHA.119.044183","article-title":"Effect of Dapagliflozin on Atrial Fibrillation in Patients with Type 2 Diabetes Mellitus: Insights from the DECLARE-TIMI 58 Trial","volume":"141","author":"Zelniker","year":"2020","journal-title":"Circulation"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/ehf2.14355","article-title":"Systematic Review of Sodium-Glucose Cotransporter 2 Inhibitors: A Hopeful Prospect in Tackling Heart Failure-Related Events","volume":"10","author":"Aziri","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/s41591-024-03374-z","article-title":"Effects of Tirzepatide on Circulatory Overload and End-Organ Damage in Heart Failure with Preserved Ejection Fraction and Obesity: A Secondary Analysis of the SUMMIT Trial","volume":"31","author":"Borlaug","year":"2025","journal-title":"Nat. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.numecd.2020.03.013","article-title":"Major Cardiovascular Events, Heart Failure, and Atrial Fibrillation in Patients Treated with Glucagon-like Peptide-1 Receptor Agonists: An Updated Meta-Analysis of Randomized Controlled Trials","volume":"30","author":"Nreu","year":"2020","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e14292","DOI":"10.1111\/eci.14292","article-title":"Glucagon-like Peptide-1 Receptor Agonist Semaglutide Reduces Atrial Fibrillation Incidence: A Systematic Review and Meta-Analysis","volume":"54","author":"Saglietto","year":"2024","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for Heart Failure with Preserved Ejection Fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e032231","DOI":"10.1161\/JAHA.123.032231","article-title":"Spironolactone Reduces the Risk of Death in Veterans with Heart Failure with Preserved Ejection Fraction","volume":"13","author":"Kurgansky","year":"2024","journal-title":"J. Am. Heart Assoc."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e016239","DOI":"10.1161\/JAHA.119.016239","article-title":"Spironolactone in Atrial Fibrillation with Preserved Cardiac Fraction: The IMPRESS-AF Trial","volume":"9","author":"Shantsila","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1161\/CIRCULATIONAHA.107.748640","article-title":"Mineralocorticoid Receptor Blockade Reverses Obesity-Related Changes in Expression of Adiponectin, Peroxisome Proliferator-Activated Receptor-Gamma, and Proinflammatory Adipokines","volume":"117","author":"Guo","year":"2008","journal-title":"Circulation"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/ehf2.12204","article-title":"Renin-Angiotensin Blockade in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis","volume":"4","author":"Khan","year":"2017","journal-title":"ESC Heart Fail."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of Candesartan in Patients with Chronic Heart Failure and Preserved Left-Ventricular Ejection Fraction: The CHARM-Preserved Trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction: A Phase 2 Double-Blind Randomised Controlled Trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1161\/CIRCHEARTFAILURE.115.002143","article-title":"Association Between Use of Statins and Mortality in Patients with Heart Failure and Ejection Fraction of \u226550","volume":"8","author":"Alehagen","year":"2015","journal-title":"Circ. Heart Fail."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1161\/CIRCULATIONAHA.110.985150","article-title":"Rapid, Direct Effects of Statin Treatment on Arterial Redox State and Nitric Oxide Bioavailability in Human Atherosclerosis via Tetrahydrobiopterin-Mediated Endothelial Nitric Oxide Synthase Coupling","volume":"124","author":"Antoniades","year":"2011","journal-title":"Circulation"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jacc.2007.10.009","article-title":"Experimental and Clinical Basis for the Use of Statins in Patients with Ischemic and Nonischemic Cardiomyopathy","volume":"51","author":"Ramasubbu","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1093\/cvr\/cvac120","article-title":"Obesity and Heart Failure with Preserved Ejection Fraction: New Insights and Pathophysiological Targets","volume":"118","author":"Borlaug","year":"2023","journal-title":"Cardiovasc. Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"ii40","DOI":"10.1093\/europace\/euaa368","article-title":"The Bidirectional Interaction between Atrial Fibrillation and Heart Failure: Consequences for the Management of Both Diseases","volume":"23","author":"Verhaert","year":"2021","journal-title":"Europace"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa2019422","article-title":"Early Rhythm-Control Therapy in Patients with Atrial Fibrillation","volume":"383","author":"Kirchhof","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/europace\/euab200","article-title":"Anticoagulation, Therapy of Concomitant Conditions, and Early Rhythm Control Therapy: A Detailed Analysis of Treatment Patterns in the EAST-AFNET 4 Trial","volume":"24","author":"Metzner","year":"2021","journal-title":"Europace"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1001\/jama.2024.17921","article-title":"Pulmonary Vein Isolation vs Sham Intervention in Symptomatic Atrial Fibrillation: The SHAM-PVI Randomized Clinical Trial","volume":"332","author":"Dulai","year":"2024","journal-title":"JAMA"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.15420\/ecr.2021.38","article-title":"Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation","volume":"17","author":"Andrade","year":"2022","journal-title":"Eur. Cardiol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1056\/NEJMoa2212540","article-title":"Progression of Atrial Fibrillation after Cryoablation or Drug Therapy","volume":"388","author":"Andrade","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1707855","article-title":"Catheter Ablation for Atrial Fibrillation with Heart Failure","volume":"378","author":"Marrouche","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1056\/NEJMoa2306037","article-title":"Catheter Ablation in End-Stage Heart Failure with Atrial Fibrillation","volume":"389","author":"Sohns","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1002\/ehf2.14488","article-title":"Conduction System Pacing and Atrioventricular Node Ablation in Heart Failure: The PACE-FIB Study Design","volume":"10","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.jchf.2025.01.029","article-title":"Effects of Atrial Fibrillation Ablation for Heart Failure with Preserved Ejection Fraction: Insights from CABANA","volume":"13","author":"Martens","year":"2025","journal-title":"JACC Heart Fail."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/pace.15221","article-title":"Atrial Fibrillation Recurrence After Catheter Ablation: The Puzzle We Have and the Pieces We Need","volume":"48","author":"Vlachakis","year":"2025","journal-title":"Pacing Clin. Electrophysiol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.120.050991","article-title":"Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure: Results from the CABANA Trial","volume":"143","author":"Packer","year":"2021","journal-title":"Circulation"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1136\/heartjnl-2016-309781","article-title":"Long-Term Efficacy of Catheter Ablation as First-Line Therapy for Paroxysmal Atrial Fibrillation: 5-Year Outcome in a Randomised Clinical Trial","volume":"103","author":"Nielsen","year":"2017","journal-title":"Heart"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/europace\/euaa298","article-title":"Catheter Ablation or Medical Therapy to Delay Progression of Atrial Fibrillation: The Randomized Controlled Atrial Fibrillation Progression Trial (ATTEST)","volume":"23","author":"Kuck","year":"2021","journal-title":"Europace"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jchf.2023.01.008","article-title":"Atrial Fibrillation Ablation for Heart Failure with Preserved Ejection Fraction: A Randomized Controlled Trial","volume":"11","author":"Chieng","year":"2023","journal-title":"JACC Heart Fail."},{"key":"ref_123","first-page":"2218","article-title":"Catheter Ablation vs Antiarrhythmic Therapy for Atrial Fibrillation in Heart Failure with Preserved Ejection Fraction","volume":"22","author":"DeLuca","year":"2024","journal-title":"Heart Rhythm."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.hrthm.2024.04.058","article-title":"Catheter Ablation versus Medical Therapy for Atrial Fibrillation in Patients with Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis","volume":"21","author":"Antunes","year":"2024","journal-title":"Heart Rhythm."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1111\/jce.15200","article-title":"Catheter Ablation for Atrial Fibrillation in HFpEF Patients\u2014A Propensity-score-matched Analysis","volume":"32","author":"Rattka","year":"2021","journal-title":"Cardiovasc. Electrophysiol."},{"key":"ref_126","first-page":"1252","article-title":"Catheter Ablation for Non-Paroxysmal Atrial Fibrillation Accompanied by Heart Failure with Preserved Ejection Fraction: Feasibility and Benefits in Functions and B-Type Natriuretic Peptide","volume":"23","author":"Yamauchi","year":"2021","journal-title":"EP Eur."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s12574-018-0399-z","article-title":"Improvement of Left Ventricular Function after Successful Radiofrequency Catheter Ablation in Persistent Atrial Fibrillation with Preserved Left Ventricular Ejection Fraction: A Comprehensive Echocardiographic Assessment Using Two-Dimensional Speckle Tracking Analysis","volume":"17","author":"Nagai","year":"2019","journal-title":"J. Echocardiogr."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Long, S., Sun, Y., Dai, S., Xiao, X., Wang, Z., Sun, W., Gao, L., Xia, Y., and Yin, X. (2025). Safety and Efficacy of Catheter Ablation in Atrial Fibrillation Patients with Heart Failure with Preserved Ejection Fraction. BMC Cardiovasc. Disord., 25.","DOI":"10.1186\/s12872-025-04494-1"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/j.jacep.2024.05.002","article-title":"Safety and Effectiveness of Pulsed Field Ablation for Atrial Fibrillation in Patients with Heart Failure","volume":"10","author":"Turagam","year":"2024","journal-title":"JACC Clin. Electrophysiol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"euad363","DOI":"10.1093\/europace\/euad363","article-title":"Ablation for Atrial Fibrillation Improves the Outcomes in Patients with Heart Failure with Preserved Ejection Fraction","volume":"26","author":"Xie","year":"2023","journal-title":"Europace"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"8332948","DOI":"10.1155\/2024\/8332948","article-title":"Long-Term Outcome of Left Heart Function after Catheter Ablation in Patients with Persistent Atrial Fibrillation Combined with Preserved Ejection Fraction Heart Failure","volume":"2024","author":"Liu","year":"2024","journal-title":"J. Interv. Cardiol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/j.jacc.2013.07.020","article-title":"Efficacy, Safety, and Outcomes of Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure with Preserved Ejection Fraction","volume":"62","author":"Seo","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1001\/jamacardio.2024.0675","article-title":"Atrial Fibrillation Ablation in Heart Failure with Reduced vs Preserved Ejection Fraction: A Systematic Review and Meta-Analysis","volume":"9","author":"Oraii","year":"2024","journal-title":"JAMA Cardiol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1161\/CIRCHEARTFAILURE.121.009281","article-title":"Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure and Preserved Ejection Fraction","volume":"15","author":"Zylla","year":"2022","journal-title":"Circ Heart Fail."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1161\/CIRCULATIONAHA.115.017119","article-title":"Effect of Selective Heart Rate Slowing in Heart Failure with Preserved Ejection Fraction","volume":"132","author":"Pal","year":"2015","journal-title":"Circulation"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/j.jacc.2021.08.073","article-title":"Effect of \u03b2-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction","volume":"78","author":"Palau","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_137","first-page":"352","article-title":"Anticoagulation for Atrial Fibrillation in Heart Failure Patients: Balancing between Scylla and Charybdis","volume":"18","author":"Tsigkas","year":"2021","journal-title":"J. Geriatr. Cardiol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/S0140-6736(22)00016-2","article-title":"Atrial Shunt Device for Heart Failure with Preserved and Mildly Reduced Ejection Fraction (REDUCE LAP-HF II): A Randomised, Multicentre, Blinded, Sham-Controlled Trial","volume":"399","author":"Shah","year":"2022","journal-title":"Lancet"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1161\/CIRCHEARTFAILURE.113.001229","article-title":"Wireless Pulmonary Artery Pressure Monitoring Guides Management to Reduce Decompensation in Heart Failure with Preserved Ejection Fraction","volume":"7","author":"Adamson","year":"2014","journal-title":"Circ Heart Fail."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/3\/969\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T05:12:11Z","timestamp":1770181931000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/3\/969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,25]]},"references-count":139,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["jcm15030969"],"URL":"https:\/\/doi.org\/10.3390\/jcm15030969","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,25]]}}}